Loxitane, Adasuve(loxapine)
Adasuve, Loxapine, Loxitane (loxapine) is a small molecule pharmaceutical. Loxapine was first approved as Loxitane im on 1982-01-01. It is used to treat psychotic disorders and schizophrenia in the USA. It has been approved in Europe to treat bipolar disorder and schizophrenia. The pharmaceutical is active against D(3) dopamine receptor, D(4) dopamine receptor, D(2) dopamine receptor, 5-hydroxytryptamine receptor 2A, and 5-hydroxytryptamine receptor 2C. In addition, it is known to target histamine H1 receptor, 5-hydroxytryptamine receptor 6, potassium channel subfamily T member 1, and 5-hydroxytryptamine receptor 7.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| mental disorders | D001523 |
Trade Name
FDA
EMA
Adasuve, Loxapine (discontinued: Loxapine, Loxitane, Loxitane c, Loxitane im)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Loxapine succinate
Loxapine hydrochloride
Loxapine
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ADASUVE | Alexza Pharmaceuticals | N-022549 RX | 2012-12-21 | 1 products, RLD, RS |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| schizophrenia | EFO_0000692 | D012559 | F20 |
| psychotic disorders | — | D011618 | F20.81 |
Agency Specific
FDA
EMA
No data
HCPCS
Code | Description |
|---|---|
| J2062 | Loxapine for inhalation, 1 mg |
Clinical
Clinical Trials
37 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Psychomotor agitation | D011595 | — | — | — | 1 | 3 | 3 | 5 | 12 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | 1 | 1 | 2 | 1 | 4 | 9 |
| Healthy volunteers/patients | — | — | — | 2 | — | — | 2 | — | 4 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | 1 | — | 2 | — | 1 | 4 |
| Emergence delirium | D000071257 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Migraine disorders | D008881 | EFO_0003821 | G43 | 1 | 2 | — | — | — | 3 |
| Neuralgia | D009437 | EFO_0009430 | — | — | 1 | — | — | — | 1 |
| Headache | D006261 | HP_0002315 | R51 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Obesity | D009765 | EFO_0001073 | E66.9 | 1 | — | — | — | — | 1 |
| Body weight | D001835 | EFO_0004338 | — | 1 | — | — | — | — | 1 |
| Weight gain | D015430 | HP_0004324 | — | 1 | — | — | — | — | 1 |
| Cardiotoxicity | D066126 | EFO_1001482 | — | 1 | — | — | — | — | 1 |
| Asthma | D001249 | EFO_0000270 | J45 | 1 | — | — | — | — | 1 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | 1 | — | — | — | — | 1 |
| Lung diseases | D008171 | HP_0002088 | J98.4 | 1 | — | — | — | — | 1 |
| Obstructive lung diseases | D008173 | HP_0006536 | — | 1 | — | — | — | — | 1 |
| Cigarette smoking | D000073865 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Psychotic disorders | D011618 | — | F20.81 | — | — | — | — | 3 | 3 |
| Mental disorders | D001523 | EFO_0000677 | F91.9 | — | — | — | — | 2 | 2 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | — | — | — | 1 | 1 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | — | — | 1 | 1 |
| Emergencies | D004630 | — | — | — | — | — | — | 1 | 1 |
| Delirium | D003693 | — | R41.0 | — | — | — | — | 1 | 1 |
| Respiratory insufficiency | D012131 | HP_0002093 | J96.9 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Loxapine |
| INN | loxapine |
| Description | Loxapine is a dibenzooxazepine. It has a role as an antipsychotic agent and a dopaminergic antagonist. |
| Classification | Small molecule |
| Drug class | tricyclic compounds |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CN1CCN(C2=Nc3ccccc3Oc3ccc(Cl)cc32)CC1 |
Identifiers
| PDB | — |
| CAS-ID | 1977-10-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL831 |
| ChEBI ID | 50841 |
| PubChem CID | 3964 |
| DrugBank | DB00408 |
| UNII ID | LER583670J (ChemIDplus, GSRS) |
Target
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Loxapine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,329 documents
View more details
Safety
Black-box Warning
Black-box warning for: Adasuve, Loxapine
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
4,385 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use